Pliant's Lead Oncology Drug PLN-101095 Shows Deep, Durable Phase 1 Responses, Accelerating Development
summarizeSummary
Pliant Therapeutics announced positive Phase 1 data for its lead oncology program, PLN-101095, in immune checkpoint inhibitor (ICI)-refractory solid tumors. The trial demonstrated deep and durable responses, including one confirmed complete response and three partial responses among 10 heavily pretreated patients. Based on these encouraging results and supportive biomarker data, the company is initiating an accelerated development plan, including a Phase 1b indication expansion trial with first patient enrollment anticipated in Q2. This significant clinical progress for a key pipeline asset in an area of high unmet medical need is a material positive catalyst for the clinical-stage biotechnology company. Investors will be watching for the upcoming AACR presentation in April 2026 and interim data from the Phase 1b trial expected in 2027.
At the time of this announcement, PLRX was trading at $1.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.7M. The 52-week trading range was $1.09 to $1.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.